Skip to content
Menu

Roth Capital Maintains Buy on BioHarvest Sciences, Lowers Price Target to $8

Benzinga Newsdesk 3 months ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.

Roth Capital analyst Sean McGowan maintains BioHarvest Sciences (NASDAQ:BHST) with a Buy and lowers the price target from $10 to $8.

Read at benzinga.com